File(s) not publicly available

Catalase immunization from Pseudomonas aeruginosa enhances bacterial clearance in the rat lung

journal contribution
posted on 06.12.2017, 00:00 by LD Thomas, ML Dunkley, R Moore, S Reynolds, DA Bastin, Jennelle KydJennelle Kyd, AW Cripps
Pseudomonas aeruginosa is a common cause of infection in immunocompromised patients and is the major contributor to morbidity in individuals with cystic fibrosis (CF). The antibiotic resistance shown by this pathogen and morbidity in patients with chronic infection has encouraged investigations into the development of a vaccine. This study reports the purification of a 60 kDa protein, isolated from a mucoid strain of P. aeruginosa, identified by amino acid sequence analysis as the catalase protein (KatA). A rat model of acute P. aeruginosa respiratory infection was used to investigate the immunogenicity of KatA and determine the potential of mucosal immunization with KatA to protect against infection. Immunization regimens compared a single intra-Peyer's patch (IPP) immunization with an IPP primary inoculation followed by an intratracheal boost to the lungs. Mucosal immunization with KatA resulted in significant pulmonary clearance of both homologous …(p < 0.001) and heterologous (p < 0.05) strains of P. aeruginosa. Both immunization regimens enhanced bacterial clearance, increased the rate of recruitment of phagocytes to the bronchoalveoli and induced KatA-specific antibody. However, the regimen that included a boost induced a more effective immune response that also resulted in better clearance of P. aeruginosa from the lungs. Mucosal immunization induced KatA- specific antibodies in the serum and the bronchoalveolar lavage, and KatA-specific lymphocyte proliferation in vitro in cells isolated from the mesenteric lymph nodes of immunized rats. The data presented suggests that KatA has the potential to afford a protective immune response against pulmonary infection by P. aeruginosa

History

Volume

19

Issue

2-3

Start Page

348

End Page

357

Number of Pages

10

ISSN

0264-410X

Location

United Kingdom

Publisher

Elsevier Ltd

Language

en-aus

Peer Reviewed

Yes

Open Access

No

Acceptance Date

29/03/2000

External Author Affiliations

University of Canberra; University of Newcastle;

Era Eligible

No

Journal

Vaccine

Usage metrics

Exports